2. 2001-20..copyright @ Transplant Creations1 Treatment & Transplant Program to improve disease outcome Transplant Creations Marlies Van Hoef

3. 2001-20..copyright @ Transplant Creations2 Introduction In the late 90s non-myeloablative allogeneic stem cell transplantation (NMT) gained interest because the procedure is associated with less treatment-related side effects than ablative allogeneic stem cell transplantation The improved tolerability offers the opportunity to integrate NMT as part of initial treatment. Implementation at this time offers to improve disease outcome Transplant Creations program supports that goal

4. 2001-20..copyright @ Transplant Creations3 Breast Cancer Introduction At the end of the 90s high-dose autologous transplants for breast cancer had received (unjust) negative press In the adjuvant setting though, a trend towards improvement of disease free survival was suggested in premenopausal women, TRM varied with the regimen An allogeneic immune response had been reported

5. 2001-20..copyright @ Transplant Creations4 Non-myeloablative Transplant Programs Protocols Program NMT for early stage disease NMT for relapse after prior autologous transplant Goal Enhance collaboration Opportunities for patients and investigators Multi-center NMT development Improve cure rates and survival

6. 2001-20..copyright @ Transplant Creations5 NMT for early Stage Disease At diagnosis: Dose intensive induction chemotherapy Two semi-high-dose autologous transplants or equivalent in leukemia A non-myeloablative reduced intensity conditioning allogeneic transplant

7. 2001-20..copyright @ Transplant Creations6 NMT for early Stage Disease indications Acute leukemia Chronic leukemia Multiple myeloma (Non-)Hodgkin lymphoma Neuroblastoma Breast cancer

8. 2001-20..copyright @ Transplant Creations7 NMT for relapse after prior autologous Transplant Compassionate use program in case at initial diagnosis no donor could be timely found The risks of treatment are increased The likelihood of survival is decreased compared to integration in the strategy from initial diagnosis We disrecommend use as the costs do in general not outweight the benefits

9. 2001-20..copyright @ Transplant Creations8 Invitation For information contact Info@transplantcreations.comInfo@transplantcreations.com or.org 0031-6-12433616

10. 2001-20..copyright @ Transplant Creations9 Contact For our services and protocols contact us: info@transplantcreations.com 0031-6-124 33616 For eligibility checks contact us: admin@transplantcreations.com